3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
3
Head & Neck
2
Gynecologic
2
Thoracic
1
Sarcoma
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
Conditions
Neuroendocrine Tumors
11
Adrenocortical Carcinoma
7
Thyroid Carcinoma, Anaplastic
5
Carcinoma, Neuroendocrine
4
Thyroid Neoplasms
3
Adrenal Cortex Neoplasms
3
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Small Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Vulvar Neoplasms
1
Vascular Neoplasms
1
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Thyroid cancer, Hurthle cell
1
Thyroid Cancer, Papillary
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Penile Neoplasms
1
Pathologic Processes
1
Parotid Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Paraganglioma
1
Neoplasms, Unknown Primary
1
Neoplasms, Germ Cell and Embryonal
1
Multiple Myeloma
1
Interventions
selpercatinib
2
Cisplatin
2
pentetreotide
1
pembrolizumab
1
entrectinib
1
cabozantinib
1
budigalimab
1
amino-acid, glucose, and electrolyte solution
1
Temozolomide
1
Tamoxifen
1
Surveys and Questionnaires
1
Rosiglitazone
1
Radiotherapy
1
Quality of Life
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Microarray Analysis
1
Immunotherapy
1
Drug Therapy
1
Doxorubicin
1
DNA Methylation
1
Carboplatin
1
Biological Therapy
1
90Y-octreotide, DOTA-Tyr(3)-
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Central Nervous System Neoplasms
×
pembrolizumab
×
Endocrine
×
Clear all
NCT03012620
2024-02-28
AcSé
UNICANCER
Phase 2
Completed
334 enrolled